Acquired Hemophilia Treatment Market by Type (Hemophilia A, Hemophilia B, and Hemophilia C), by Therapy (Gene Therapy, Immune Tolerance Induction Therapy, Replacement Therapy, and Others), by Treatment (On-Demand and Prophylaxis), and by End-User (Hospitals and Clinics) – Global Outlook & Forecast 2022-2030
According to the deep-dive market assessment study conducted by Growth+ Reports, the global acquired hemophilia treatment market was pegged at ~US$ 11 billion in 2021. The market is expected to witness a CAGR of ~5.06% from 2022 to 2030.
Acquired hemophilia (AH) is a genetic disease in which the coagulating protein is affected. In AH, the immune system attacks the clotting inhibitor/antibodies (factors such as VIII, IX, or XIII). Various therapies are performed for the treatment of acquired hemophilia such as plasma-derived therapy, recombinant therapy, desmopressin, antifibrinolytic agents, and many more. Furthermore, different modes of treatment such as on-demand treatment and prophylaxis treatment are available in the market.
The continuous hike in the cases of acquired hemophilia in the global population and a rising awareness in diagnosis and treatment of rare diseases have helped in the significant growth of the market globally. Governments, and private organizations have also been extending tremendous support in form of funds and investment to develop & provide better and more efficient acquired hemophilia treatments. For instance, in December 2020, Takeda Pharmaceutical Company Limited announced the U.S. Foods and Drugs Administration (FDA) approval to myPKFiT for ADYNOVATE, a web-based software and mobile application i.e., pharmacokinetic (PK)-dosing software for hemophilia A patients. This software helps healthcare professionals to estimate the full PK curve (Pharmacokinetic Curve).
The research on hemophilia treatment and growing interest in the field of technological development proves to be a beneficial factor for this market growth. The advancement in the therapeutics is an essential step in the market development because of the rising prevalence of acquired hemophilia around the globe. In February 2020, Novo Nordisk launched a U.S. FDA approved product namely “ESPEROCT”, which focuses on the treatment of hemophilia A. This new therapy helps to reduce the frequency of bleeding and also can be used in on-demand cases.
The incidence of acquired hemophilia is expected to grow during the forecast period. Acquired hemophilia more commonly occurs in males, as females commonly are the carriers of this malfunctioning gene. The growth in the number of patients has a great impact on the market and can be considered as a leading factor in propelling the market growth globally. For instance, according to the 2020 report of the U.S. National Library of Medicine, the incidence of acquired hemophilia in children (age group from 1-16 years) is 0.045 per million per year and 14.7 per million per year (age group from 17-85 years old).
However, there are some growth challenges in this market such as high treatment costs, inadequate knowledge of the technology, lack of awareness in the developing countries, and so on. Among other challenges, the high cost of the treatment can be considered a leading issue that can drop the market value. The lack of treatment due to the expensive therapies and diagnoses will be a major impacting factor for this market. Due to high prices, the patients in low-income countries may not fully avail advanced treatments for acquired hemophilia. Thus, this situation can adversely affect the adoption rate of treatment, thereby negatively impacting the global acquired hemophilia treatment market.
North America holds the largest revenue share in the global acquired hemophilia market. The dominant position of North America is attributed to better healthcare infrastructure and growth in research & development (R&D) activities; while Asia Pacific (APAC) is estimated to be the fastest-growing region in the global market. The growth of the region is mainly attributed to the growth in cases of hemophilic patients, advancements in the infrastructure & products, and growing awareness. Moreover, emerging government initiatives lead to the rapid adoption of acquired hemophilia treatment by usurping the market globally. Additionally, improvised diagnostic techniques, rising adoption of prophylaxis, a vast research base, etc. can be a few reasons for the upward growth in the global market.
Some of the prominent players operating in the global acquired hemophilia treatment market are Pfizer, Inc., Genentech Inc., CSL Behring, Biogen Idec, Inc., Baxter International, Inc., Hospira, Inc., Novo Nordisk AS, Biotest AG., Octapharma AG and Spark Therapeutics Inc. among others.